Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of stigmasterol to preparation of medicine for improving cardiac hypertrophy

A technique of myocardial hypertrophy and stigmasterol, which is applied in the field of biomedicine, can solve the problems of poor therapeutic effect of myocardial hypertrophy and increased risk of sudden death of patients, and achieves the goal of inhibiting myocardial hypertrophy, inhibiting oxidative stress of myocardial cells, and improving myocardial hypertrophy. Effect

Active Publication Date: 2021-07-23
GUANGDONG PHARMA UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, when high blood pressure causes cardiac hypertrophy, antihypertensive drugs are often used for treatment. After intervention, blood pressure can be controlled in the normal range, but the treatment effect on cardiac hypertrophy is not very good, and cardiac hypertrophy will inevitably gradually develop into chronic heart failure. Increased risk of sudden death in patients
However, there is no relevant report on the use of stigmasterol in the preparation of drugs for improving cardiac hypertrophy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of stigmasterol to preparation of medicine for improving cardiac hypertrophy
  • Application of stigmasterol to preparation of medicine for improving cardiac hypertrophy
  • Application of stigmasterol to preparation of medicine for improving cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Cytotoxicity detection of embodiment 1 stigmasterol

[0045] 1. Culture and passage of H9c2 cells

[0046] In an incubator maintained at constant temperature and humidity, culture was carried out with an appropriate proportion of Dulbecco's Modified Eagle's Medium (DMEM). When the cells were in good condition and the cell density reached 80-90%, subculture was carried out, the culture supernatant was discarded, washed twice with high-pressure phosphate buffered saline (PBS) with a pipette gun, and 1 mL of trypsin was absorbed for digestion. When most of the cells were observed to shrink under the microscope, 2 mL of medium was added to the ultra-clean bench to stop the digestion, the adherent cells were blown off with a pipette gun, and transferred to a 5 mL EP tube for centrifugation at 1500 rpm / min for 5 min. Discard the supernatant, add 2mL medium to resuspend, and carry out passage according to the ratio of 1:3.

[0047] 2. Cell Viability Detection

[0048] Cell ...

Embodiment 2

[0053] Embodiment 2 in vitro exploration experiment

[0054] 1. Immunofluorescence of cells

[0055] H9c2 cells were pretreated with 0.5 μg / mL (low), 2.5 μg / mL (medium) and 5 μg / mL (high) stigmasterol (STG) for 30 min, and then stimulated with ISO for 48 hours to observe the effect of stigmasterol on ISO-induced H9c2 cells. The effect of cardiomyocyte surface area, the specific steps are as follows:

[0056] (1) Take H9c2 cardiomyocytes in a good growth state, digest and resuspend them into a cell suspension, adjust the cell density to 6000 per well, plant them in a 48-well plate (the well plate is equipped with a small round glass slide with a radius of 4mm), About 12 hours after the cells were completely adhered to the wall, they were divided into blank, model, and administration groups (stigmasterol was added at least 30 minutes in advance in the administration group), and 10 μM ISO was added to each well of the model and administration groups for 48 hours;

[0057] (2) A...

Embodiment 3

[0082] Example 3 Stigmasterol inhibits the oxidative stress of ISO-induced H9c2 mast cells

[0083] A large number of studies have shown that the process of cardiac hypertrophy is often accompanied by an increase in oxidative stress. Therefore, the present invention adopts malondialdehyde MDA kit (article number A003-2) and superoxide dismutase SOD kit (article number A001-3) produced by Nanjing Jiancheng Company to detect the impact of ISO on the oxidative stress of H9c2 cells respectively. As well as the intervention effect of stigmasterol on the oxidative stress caused by ISO, the specific steps are carried out with reference to the instructions. The result is as image 3 As shown in A and 3B, compared with the CON group, the level of MDA in the cells of the ISO group was significantly increased, while the level of SOD was significantly reduced; compared with the ISO group, the stigmasterol pretreatment group, especially the high-dose treatment group (5μg / mL), can signif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of stigmasterol to preparation of a medicine for improving cardiac hypertrophy. According to the invention, in-vitro experimental studies show that the stigmasterol can relieve ISO-induced H9c2 cell hypertrophy and can inhibit an oxidative stress reaction in ISO-induced H9c2 cells so as to take an effect of inhibiting cardiaccell hypertrophy; and further in-vivo experiments show that the stigmasterol can obviously relieve ISO-induced cardiacremodeling of mice and inhibit cardiac tissue fibrosis of the mice so as to improve cardiac hypertrophy. Therefore, the stigmasterol can be combined with other medicine auxiliary materials to prepare medicines in different dosage forms, and the prepared medicines can be used for improving cardiac hypertrophy.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of stigmasterol in the preparation of drugs for improving cardiac hypertrophy. Background technique [0002] A large number of studies have shown that soybean oil has strong antioxidant activity, can effectively scavenge free radicals, improve blood lipids, and protect blood vessels. Eating soybean oil can prevent obesity, cardiovascular diseases and many other diseases. Stigmasterol is an important nutrient in soybean oil, which belongs to phytosterols. Studies have shown that it has many activities such as lowering cholesterol, treating fatty liver, anti-inflammation, and anti-tumor; in addition, compound soybean sterol tablets (a mixture of stigmasterol and other pharmaceutical ingredients ) can lower blood lipid levels, inhibit the development of atherosclerosis, and have therapeutic effects on hyperlipidemia, coronary arteriosclerotic hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P9/04
CPCA61K31/575A61P9/04
Inventor 李春梅孙宇汪帅李咏琪胡刚
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products